GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
The risk of cardiovascular disease (CVD) (myocardial infarction, stroke, peripheral vascular disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects. Furthermore, cardiovascular disease (CV) is the leading cause of death in patients with T2D.In the last years several clinical intervention studies with new anti-hyperglycaemic drugs have been published, and they have shown a positive effect on the reduction of mortality and cardiovascular risk in T2D patients. In particular, these studies evaluated sodium/glucose-2 cotransporter inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA).In secondary prevention, it was clearly demonstrated that SGLT2i and GLP-1RA drugs reduce CV events and mortality, and new guidelines consider now these drugs as first choice (after metformin) in the treatment of T2D; there are also some signs that they may be effective also in primary prevention of CVD. However, the mechanisms involved in cardiovascular protection are not yet fully understood, but they appear to be both "glycaemic" and "extra-glycaemic".In this review, we will examine the fundamental results of the clinical trials on SGLT2i and GLP-1RA, their clinical relevance in term of treatment of T2D, and we will discuss the mechanisms that may explain how these drugs exert their cardiovascular protective effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regulating immune signaling pathways prevents inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) from producing and releasing.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [29]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Cited by
European Society of Cardiology: cardiovascular disease statistics 2021
Timmis, A., Vardas, P., Townsend, N., Torbica, A., Katus, H., De Smedt, D., Gale, C. P., Maggioni, A. P., Petersen, S. E., Huculeci, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab892 · Cited by 1,102
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Gourdy, P., Darmon, P., Diévart, F., Halimi, J., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 157
Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies
Dwivedi, S., & Sikarwar, M. S. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2435-8264 · Cited by 165
Vesa, C. M., Popa, L., Popa, A. R., Rus, M., Zaha, A. A., BUNGAU, S. G., Ţiţ, D. M., Aron, R. A. C., & Zaha, D. C. (2020) · Diagnostics · doi:10.3390/diagnostics10050314 · Cited by 107
Li, C., Jie, L., Jiang, M., & Wang, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838277 · Cited by 114
GLP-1 agonists for weight loss: pharmacology and clinical implications.
Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02394-w · Cited by 86
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66
Iacobellis, G., & Baroni, M. G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 56
Self-citationImpact of Dysfunctional Adipose Tissue Depots on the Cardiovascular System
D’Oria, R., Genchi, V. A., Caccioppoli, C., CALDERONI, I., Marrano, N., Biondi, G., Borrelli, A., Gioia, L. D., Giorgino, F., & Laviola, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214296 · Cited by 43
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
“Since GLP-1RAs are among the most expensive drugs used in the treatment of T2DM and obesity, cost-effectiveness analysis should also be pursued in these studies.”
BackgroundInfluentialMousavi, A., Shojaei, S., Soleimani, H., Semirani-Nezhad, D., Ebrahimi, P., Zafari, A., Ebrahimi, R., Roozbehi, K., Harrison, A., Syed, M., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01635-6 · Cited by 44
GLP‐1 agonists and the gut microbiome: A bidirectional relationship
Kamath, S., Chan, N. S. L., & Joyce, P. M. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70487 · Cited by 42
Liu, F., Yang, Q., Zhang, H., Zhang, Y., Yang, G., Ban, B., Li, Y., & Zhang, M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0270899 · Cited by 30
Heiß, C., Olinic, D.-M., Belch, J. J. F., Brodmann, M., Mazzolai, L., Stanek, A., Maďarič, J., Krentz, A. J., Schlager, O., Lichtenberg, M. K. W., et al. (2022) · VASA · doi:10.1024/0301-1526/a000998 · Cited by 29
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 33
Janjusevic, M., Fluca, A. L., Gagno, G., Pierri, A., Padoan, L., Sorrentino, A., Beltrami, A. P., Sinagra, G., & Aleksova, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042336 · Cited by 24
Premji, R., Nylen, E. S., Naser, N., Gandhi, S., Burman, K. D., & Sen, S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0004 · Cited by 18
“…complications, including CVD. 58 Both GLP1a and SGLT2i are both weight-reducing agents with supporting evidence for cardiovascular bene-fit, 59,60 but they are both expensive drugs, and there is little evidence to guide therapy with one agent over the other in different racial groups,…”
Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors
Yang, F., Meng, R., & Zhu, D. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.07.002 · Cited by 19
Zhao, M., Liu, C., Feng, Y., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.946415 · Cited by 24
Kaisang, L., Zhang, W., He, F., & Shen, J. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/8149515 · Cited by 15
Diabetes: from Research to Clinical Practice
(2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51089-3 · Cited by 6
Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome
Ravić, M. P., Srejovic, I. M., Novakovic, J. N., Andjic, M. M., Sretenovic, J. Z., Muric, M. D., Nikolic, M. R., Bolevich, S., Касабов, К. А., Фисенко, В. П., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17040525 · Cited by 7
Xie, Y., Kuang, J., Li, Q., Hong, T., Ji, L., Kong, Y., Duan, Y., & Chen, L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069080 · Cited by 5
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Renin-Angiotensin Aldosterone System Modulation and Cardiovascular-Kidney-Metabolic HealthPreprint
Mochel, J. P. (2024) · Preprints.org · doi:10.20944/preprints202406.2075.v1 · Cited by 1
Nanomaterial in the Management of Diabetes
Maheshwari, S., Singh, A. N., Verma, A., Akhtar, J., Mandal, P., Yadav, J. P., & Prajapati, B. G. (2025) · Smart nanomaterials technology · doi:10.1007/978-981-96-2112-5_11 · Cited by 1
The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Luca, S. A., Bungau, R. M., Lazăr, S., Herascu, A., Gaiţă, L., Avram, V. F., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196877 · Cited by 1
Nama, L., Abubakar, M., Daksh, R., Goel, G., Gajbhiye, R. L., Kumar, P., Rai, A., Murti, K., Ravichandiran, V., & Kumar, N. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10781-8 · Cited by 1
Xu, P., Dong, C., Xu, X., Zheng, K., Liu, Q., Duan, Y., Hu, Z., Bao, L., & Zhang, B. (2026) · International Journal of Endocrinology · doi:10.1155/ije/7060233 · Cited by 1
The impact of GLP-1 analogues on cardiovascular risk
Kołakowska, K., Miłkowska, U., Piech, G. M., & Lis, I. (2024) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2024-0030 · Cited by 1
Adipositas- und Metabolische Chirurgie als Option im Konzept gegen Diabetes
Stirban, O. A., & Horbach, T. (2020) · Info Diabetologie · doi:10.1007/s15034-020-2111-4
Martins, J. B., Bernardes, A. F. D. M., Perri, L. M. D. M., Vieira, M. R., Oliveira, O. G. P. C. D., Ferreira, P. H. T., & Marques, R. T. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n5-213 · Cited by 4
Managing TIA: Early action and essential risk-reduction steps
Rundell (2022) · The Journal of Family Practice · doi:10.12788/jfp.0398
Glp-1 Analogs for the Treatment of Obesity and Diabetes
Belloni, J., & Tapper, X. (2022) · Endocrinology and Disorders · doi:10.31579/2640-1045/116
Peripheral arterial disease and the cardiometabolic syndrome: assessment and management
Heiß, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00015-2
AMARA, M. D. S. S. M. F. (2023) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2023.318285
Yen, F., Wei, J. C.-C., Hung, Y., Li, P.-Y., Hsu, C., & Hwu, C. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09847-2
Zhou, L., Qu, H., Yang, L., & Shou, L. (2024) · Figshare · doi:10.6084/m9.figshare.26637207
Abdu, F. A., Hu, H., & Lu, P. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121009
Moreno, K., Gualán, J., Toapanta, J., & Barahona, A. S. C. (2026) · Innova Science Journal · doi:10.63618/omd/isj/v4/n2/252 · Cited by 5
Mohanty, S. S., Selvammathy, R. R., Ahad, H. A., & Kumar, E. S. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_1384_25 · Cited by 4
Chen, X. T., Tu, B. B., Li, Z., Gao, P., Xu, Y., & Yao, Y. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl49873
Tabatabaei, S. A. D., & Tabatabaei, M. D. (2026) · Clinical Cardiology · doi:10.1002/clc.70509
Metadata
- Authors
- Bertoccini, L., & Baroni, M. G.
- Affiliations
- Sapienza University of Rome (IT)
- Istituto Neurologico Mediterraneo (IT)
- Corresponding author
- Baroni, Marco Giorgio
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer International Publishing
- Published
- 2020
- Volume
- 1307
- Pages
- 193-212
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W3004875823
- Cited by
- 49
- References
- 83
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 13 · 2021: 4 · 2020: 6
- FWCI
- 31.56
- Type
- book chapter
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, cardioprotection, cardiovascular risk reduction, myocardial infarction, stroke, mortality, secondary prevention, primary prevention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.